Nanjing, China (June 17, 2024) At the recent European League Against Rheumatism (EULAR) Congress in Vienna, Austria, Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) delivered an oral presentation on its highly innovative therapeutic candidate LBL-047. LBL-047 is a first-in-class, long-acting TACI/BD

Nanjing, China, June 2 (Chicago) and June 3 (Beijing), 2024 - The annual meeting of the American Society of Clinical Oncology (ASCO) commenced on May 31st, Showcasing groundbreaking cancer research from around the world. According to official information, over 7,000 abstracts were submitted this yea

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 31 to June 4, 2024. As the largest and most academically prestigious international oncology conference in the world, the ASCO Annual Meeting gathers the latest and most cutting-edge research finding

NANJING, China, April 30, 2024--Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by Leads Biolabs with global intellectual property rights has received approval to conduct the single-a

American Association for Cancer Research® (AACR) annual meeting is the largest cancer research conference in the world. The 2024 AACR annual meeting will be held in San Diego, USA, from April 5th to 10th to share the latest advancements in cancer and related biomedical sciences. Nanjing Leads Biolab

American Association for Cancer Research® (AACR) annual meeting 2024 will be held in San Diego, USA from April 5 to 10, 2024, EST. Renowned as one of the largest academic events in cancer research, AACR annual meeting attracts tens of thousands of professionals from all over the world every year, di

The annual meeting of the American Society of Hematology (ASH) is the largest and most comprehensive international academic event in the field of hematology in the world. The 65th annual meeting of ASH will be held in San Diego, USA from December 9 to 12, 2023. Nanjing Leads Biolabs (Leads Biolabs)

The Annual Meeting of Society for Immunotherapy of Cancer (SITC) is the largest international event focusing on cancer immunotherapy in the world, attracting more than 3,500 participants each year from academia, regulatory authorities and government agencies. At this year's SITC Annual Meeting, whic

NANJING, China, July 31, 2023--Nanjing Leads Biolabs Co.，Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") announced today that the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) have approved its first-in-human Investigational New Drug (

The U.S. FDA Approved the Phase I/II Clinical Trial Application to Evaluate LBL-033, An Anti-MUC16/CD3 Bispecific Antibody Developed by Leads Biolabs, in Advanced Solid Tumors Including Ovarian Cancer